Lineage Cell Therapeutics, Inc. (LCTX)
1.025
+0.08
(+8.17%)
USD |
NYAM |
Oct 08, 16:00
1.025
0.00 (0.00%)
After-Hours: 18:44
Lineage Cell Therapeutics Net Income (Quarterly) : 1.544M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.544M |
| March 31, 2026 | -4.789M |
| December 31, 2025 | 0.892M |
| September 30, 2025 | -29.75M |
| June 30, 2025 | -30.36M |
| March 31, 2025 | -4.143M |
| December 31, 2024 | -3.25M |
| September 30, 2024 | -3.001M |
| June 30, 2024 | -5.773M |
| March 31, 2024 | -6.558M |
| December 31, 2023 | -4.714M |
| September 30, 2023 | -7.158M |
| June 30, 2023 | -5.203M |
| March 31, 2023 | -4.404M |
| December 31, 2022 | -6.362M |
| September 30, 2022 | -6.116M |
| June 30, 2022 | -6.782M |
| March 31, 2022 | -7.093M |
| December 31, 2021 | -29.19M |
| September 30, 2021 | -7.834M |
| June 30, 2021 | -4.796M |
| March 31, 2021 | -1.448M |
| December 31, 2020 | 2.045M |
| September 30, 2020 | -7.772M |
| June 30, 2020 | -6.53M |
| Date | Value |
|---|---|
| March 31, 2020 | -8.428M |
| December 31, 2019 | -4.556M |
| September 30, 2019 | -16.52M |
| June 30, 2019 | -30.05M |
| March 31, 2019 | 39.30M |
| December 31, 2018 | -44.98M |
| September 30, 2018 | 66.54M |
| June 30, 2018 | -4.646M |
| March 31, 2018 | -63.70M |
| December 31, 2017 | -72.07M |
| September 30, 2017 | 13.99M |
| June 30, 2017 | -12.23M |
| March 31, 2017 | 47.02M |
| December 31, 2016 | -7.741M |
| September 30, 2016 | 29.26M |
| June 30, 2016 | 21.22M |
| March 31, 2016 | -24.00M |
| December 31, 2015 | -16.80M |
| September 30, 2015 | -16.74M |
| June 30, 2015 | -12.00M |
| March 31, 2015 | -12.59M |
| December 31, 2014 | -12.78M |
| September 30, 2014 | -9.952M |
| June 30, 2014 | -11.39M |
| March 31, 2014 | -9.728M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
| Imunon, Inc. | -2.814M |
| Curis, Inc. | -8.581M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.069M |
| Total Expenses (Quarterly) | -0.413M |
| EPS Diluted (Quarterly) | -0.0304 |
| Enterprise Value | 190.01M |
| Gross Profit Margin (Quarterly) | 82.51% |
| Earnings Yield | -17.98% |
| Normalized Earnings Yield | -13.50 |